Pacific Shuanglin Bio-pharmacy Co., LTD (SHE:000403)

Market Cap	17.11B
Revenue (ttm)	2.50B
Net Income (ttm)	654.13M
Shares Out	950.40M
EPS (ttm)	0.70
PE Ratio	25.88
Forward PE	15.65
Dividend	0.38 (2.14%)
Ex-Dividend Date	Jun 4, 2025

Volume	16,126,613
Average Volume	14,443,002
Open	17.75
Previous Close	17.63
Day's Range	17.53 - 18.05
52-Week Range	14.97 - 20.96
Beta	0.67
RSI	51.19
Earnings Date	Aug 27, 2025

About SHE:000403

Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation. The c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 2,635
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000403

Financial Performance

In 2024, SHE:000403's revenue was 2.65 billion, an increase of 14.00% compared to the previous year's 2.33 billion. Earnings were 745.32 million, an increase of 21.76%.